|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zbar B, Klausner R and Linehan WM:
Studying cancer families to identify kidney cancer genes. Annu Rev
Med. 54:217–233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Myers MP, Pass I, Batty IH, et al: The
lipid phosphatase activity of PTEN is critical for its tumor
supressor function. Proc Natl Acad Sci USA. 95:13513–13518. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra
S and Mandal AK: Aberrant promoter methylation and inactivation of
PTEN gene in cervical carcinoma from Indian population. J Cancer
Res Clin Oncol. 137:1255–1262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brenner W, Färber G, Herget T, Lehr HA,
Hengstler JG and Thüroff JW: Loss of tumor suppressor protein PTEN
during renal carcinogenesis. Int J Cancer. 99:53–57. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki A, de la Pompa JL, Stambolic V, et
al: High cancer susceptibility and embryonic lethality associated
with mutation of the PTEN tumor suppressor gene in mice. Curr Biol.
8:1169–1178. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Backman SA, Ghazarian D, So K, et al:
Early onset of neoplasia in the prostate and skin of mice with
tissue-specific deletion of Pten. Proc Natl Acad Sci USA.
101:1725–1730. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li G, Robinson GW, Lesche R, et al:
Conditional loss of PTEN leads to precocious development and
neoplasia in the mammary gland. Development. 129:4159–4170.
2002.PubMed/NCBI
|
|
12
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Itoh N, Semba S, Ito M, Takeda H, Kawata S
and Yamakawa M: Phosphorylation of Akt/PKB is required for
suppression of cancer cell apoptosis and tumor progression in human
colorectal carcinoma. Cancer. 94:3127–3134. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurose K, Zhou XP, Araki T, Cannistra SA,
Maher ER and Eng C: Frequent loss of PTEN expression is linked to
elevated phosphorylated Akt levels, but not associated with p27 and
cyclin D1 expression, in primary epithelial ovarian carcinomas. Am
J Pathol. 158:2097–2106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanamori Y, Kigawa J, Itamochi H, et al:
Correlation between loss of PTEN expression and Akt phosphorylation
in endometrial carcinoma. Clin Cancer Res. 7:892–895.
2001.PubMed/NCBI
|
|
16
|
Ringel MD, Hayre N, Saito J, et al:
Overexpression and overactivation of Akt in thyroid carcinoma.
Cancer Res. 61:6105–6111. 2001.PubMed/NCBI
|
|
17
|
Hager M, Haufe H, Kemmerling R, et al:
Increased activated Akt expression in renal cell carcinomas and
prognosis. J Cell Mol Med. 13:2181–2188. 2009. View Article : Google Scholar
|
|
18
|
Datta SR, Dudek H, Tao X, et al: Akt
phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
del Peso L, González-García M, Page C,
Herrera R and Nuñez G: Interleukin-3-induced phosphorylation of BAD
through the protein kinase Akt. Science. 278:687–689. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cardone MH, Roy N, Stennicke HR, et al:
Regulation of cell death protease caspase-9 by phosphorylation.
Science. 282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR,
Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis
factor requires the Akt serine-threonine kinase. Nature. 401:82–85.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Romashkova JA and Makarov SS: NF-kappaB is
a target of AKT in anti-apoptotic PDGF signalling. Nature.
401:86–90. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ashcroft M, Ludwig RL, Woods DB, et al:
Phosphorylation of HDM2 by Akt. Oncogene. 21:1955–1962. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Waite KA and Eng C: Protean PTEN: form and
function. Am J Hum Genet. 70:829–844. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mayo LD and Donner DB: A
phosphatidylinositol 3-kinase/Akt pathway promotes translocation of
Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA.
98:11598–11603. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mayo LD, Dixon JE, Durden DL, Tonks NK and
Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells
to chemotherapy. J Biol Chem. 277:5484–5489. 2002. View Article : Google Scholar
|
|
28
|
Velickovic M, Delahunt B, McIver B and
Grebe SK: Intragenic PTEN/MMAC1 loss of heterozygosity in
conventional (clear-cell) renal cell carcinoma is associated with
poor patient prognosis. Mod Pathol. 15:479–485. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirata H, Hinoda Y, Ueno K, Majid S, Saini
S and Dahiya R: Role of secreted frizzled-related protein 3 in
human renal cell carcinoma. Cancer Res. 70:1896–1905. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Martinez-Salamanca JI, Huang WC, Millan I,
Bertini R, Bianco FJ, Carballido JA, et al: Prognostic impact of
the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with
venous extension. Eur Urol. 59:120–127. 2011. View Article : Google Scholar
|
|
31
|
Georgescu MM: PTEN tumor suppressor
network in PI3K-Akt pathway control. Genes Cancer. 1:1170–1177.
2010. View Article : Google Scholar
|
|
32
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: a link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ko LJ and Prives C: p53: puzzle and
paradigm. Genes Dev. 10:1054–1072. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wallace-Brodeur RR and Lowe SW: Clinical
implications of p53 mutations. Cell Mol Life Sci. 55:64–75. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tomasino RM, Morello V, Tralongo V, et al:
p53 expression in human renal cell carcinoma: an
immunohistochemical study and a literature outline of the
cytogenetic characterization. Pathologica. 86:227–233.
1994.PubMed/NCBI
|
|
36
|
Vasavada SP, Novick AC and Williams BR:
P53, bcl-2 and Bax expression in renal cell carcinoma. Urology.
51:1057–1061. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roberts AM, Watson IR, Evans AJ, Foster
DA, Irwin MS and Ohh M: Suppression of hypoxia-inducible factor
2alpha restores p53 activity via Hdm2 and reverses chemoresistance
of renal carcinoma cells. Cancer Res. 69:9056–9064. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogawara Y, Kishishita S, Obata T, et al:
Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J
Biol Chem. 277:21843–21850. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mayo LD and Donner DB: The PTEN, Mdm2, p53
tumor suppressor-oncoprotein network. Trends Biochem Sci.
27:462–467. 2002. View Article : Google Scholar : PubMed/NCBI
|
